Concepts (108)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 4 | 2020 | 384 | 1.280 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 546 | 1.040 |
Why?
|
| Internship and Residency | 2 | 2018 | 283 | 0.970 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2019 | 14 | 0.760 |
Why?
|
| Medical Oncology | 2 | 2020 | 70 | 0.760 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 208 | 0.740 |
Why?
|
| Tibial Nerve | 1 | 2020 | 16 | 0.730 |
Why?
|
| Taxoids | 1 | 2020 | 47 | 0.720 |
Why?
|
| Sural Nerve | 1 | 2020 | 22 | 0.720 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2019 | 4 | 0.710 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2019 | 7 | 0.710 |
Why?
|
| Median Nerve | 1 | 2020 | 44 | 0.710 |
Why?
|
| Mouth Neoplasms | 1 | 2019 | 15 | 0.710 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2020 | 45 | 0.710 |
Why?
|
| Communication | 1 | 2020 | 122 | 0.690 |
Why?
|
| Physician-Patient Relations | 1 | 2020 | 169 | 0.670 |
Why?
|
| Teaching | 1 | 2018 | 55 | 0.650 |
Why?
|
| Ultrasonography | 1 | 2020 | 347 | 0.610 |
Why?
|
| Internal Medicine | 1 | 2017 | 45 | 0.590 |
Why?
|
| Sulfides | 1 | 2016 | 24 | 0.580 |
Why?
|
| Caprylates | 1 | 2016 | 25 | 0.580 |
Why?
|
| Curriculum | 1 | 2017 | 196 | 0.530 |
Why?
|
| Physicians | 1 | 2017 | 135 | 0.520 |
Why?
|
| Lung | 1 | 2016 | 233 | 0.510 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 327 | 0.470 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 667 | 0.470 |
Why?
|
| Neoplasms | 2 | 2018 | 612 | 0.450 |
Why?
|
| Humans | 13 | 2020 | 29213 | 0.330 |
Why?
|
| Pilot Projects | 2 | 2020 | 478 | 0.300 |
Why?
|
| Aged | 6 | 2020 | 9510 | 0.270 |
Why?
|
| Weight Loss | 1 | 2008 | 414 | 0.250 |
Why?
|
| Brain Neoplasms | 2 | 2020 | 587 | 0.240 |
Why?
|
| Male | 8 | 2020 | 17872 | 0.210 |
Why?
|
| Middle Aged | 6 | 2020 | 10868 | 0.190 |
Why?
|
| Reference Standards | 1 | 2020 | 30 | 0.190 |
Why?
|
| Microglia | 1 | 2020 | 48 | 0.180 |
Why?
|
| Ankle | 1 | 2020 | 22 | 0.180 |
Why?
|
| Epidermis | 1 | 2020 | 23 | 0.180 |
Why?
|
| Albumins | 1 | 2020 | 38 | 0.180 |
Why?
|
| Forearm | 1 | 2020 | 33 | 0.180 |
Why?
|
| Immunity, Innate | 1 | 2020 | 64 | 0.180 |
Why?
|
| Electrodiagnosis | 1 | 2020 | 35 | 0.180 |
Why?
|
| Nerve Fibers | 1 | 2020 | 30 | 0.180 |
Why?
|
| Wrist | 1 | 2020 | 39 | 0.180 |
Why?
|
| Paclitaxel | 1 | 2020 | 50 | 0.180 |
Why?
|
| Leg | 1 | 2020 | 56 | 0.180 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2019 | 3 | 0.180 |
Why?
|
| Laryngeal Neoplasms | 1 | 2019 | 11 | 0.180 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 17 | 0.180 |
Why?
|
| Papillomaviridae | 1 | 2019 | 17 | 0.180 |
Why?
|
| Neural Conduction | 1 | 2020 | 81 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2008 | 1382 | 0.170 |
Why?
|
| Cranial Irradiation | 1 | 2019 | 84 | 0.170 |
Why?
|
| Papillomavirus Infections | 1 | 2019 | 52 | 0.170 |
Why?
|
| Risk | 1 | 2019 | 290 | 0.170 |
Why?
|
| Interprofessional Relations | 1 | 2018 | 48 | 0.160 |
Why?
|
| Female | 7 | 2020 | 18236 | 0.160 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 681 | 0.160 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 142 | 0.160 |
Why?
|
| Nicotine | 1 | 2020 | 158 | 0.160 |
Why?
|
| Nervous System Diseases | 1 | 2018 | 37 | 0.160 |
Why?
|
| Immunotherapy | 1 | 2018 | 69 | 0.160 |
Why?
|
| Energy Intake | 2 | 2008 | 120 | 0.150 |
Why?
|
| Attitude of Health Personnel | 1 | 2018 | 163 | 0.150 |
Why?
|
| Topotecan | 1 | 2016 | 15 | 0.150 |
Why?
|
| Education, Medical | 1 | 2017 | 67 | 0.140 |
Why?
|
| Educational Measurement | 1 | 2017 | 111 | 0.140 |
Why?
|
| Clinical Competence | 1 | 2018 | 307 | 0.140 |
Why?
|
| Adult | 5 | 2019 | 8466 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 836 | 0.140 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 1365 | 0.140 |
Why?
|
| Prospective Studies | 1 | 2020 | 2027 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 337 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 401 | 0.110 |
Why?
|
| Neoplasm Metastasis | 2 | 2020 | 199 | 0.080 |
Why?
|
| United States | 1 | 2017 | 3648 | 0.080 |
Why?
|
| Agaricales | 1 | 2007 | 1 | 0.080 |
Why?
|
| Meat | 1 | 2007 | 15 | 0.080 |
Why?
|
| Baltimore | 1 | 2008 | 49 | 0.080 |
Why?
|
| Dietary Fats | 1 | 2007 | 108 | 0.080 |
Why?
|
| Overweight | 1 | 2007 | 259 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2008 | 252 | 0.070 |
Why?
|
| Adolescent | 2 | 2008 | 3265 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2019 | 3726 | 0.050 |
Why?
|
| Retrospective Studies | 2 | 2019 | 3121 | 0.050 |
Why?
|
| Chemokine CCL20 | 1 | 2020 | 3 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 18 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2020 | 22 | 0.050 |
Why?
|
| Obesity | 1 | 2007 | 1068 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 160 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2008 | 3108 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2020 | 80 | 0.050 |
Why?
|
| Cell Transformation, Viral | 1 | 2019 | 4 | 0.050 |
Why?
|
| Mice, Nude | 1 | 2020 | 276 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 53 | 0.040 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 141 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 437 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 709 | 0.040 |
Why?
|
| Prognosis | 1 | 2019 | 1363 | 0.030 |
Why?
|
| Prevalence | 1 | 2018 | 907 | 0.030 |
Why?
|
| Mice | 1 | 2020 | 2372 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 1694 | 0.030 |
Why?
|
| Animals | 1 | 2020 | 7302 | 0.020 |
Why?
|
| Satiety Response | 1 | 2007 | 1 | 0.020 |
Why?
|
| Thinness | 1 | 2007 | 31 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2007 | 95 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2007 | 454 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2007 | 159 | 0.020 |
Why?
|